Compare FTNT & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTNT | ARGX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5B | 52.0B |
| IPO Year | 2009 | 2017 |
| Metric | FTNT | ARGX |
|---|---|---|
| Price | $85.71 | $707.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 26 | 19 |
| Target Price | $88.28 | ★ $991.56 |
| AVG Volume (30 Days) | ★ 5.0M | 312.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.08 | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $6,799,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.55 | $22.38 |
| P/E Ratio | $34.93 | ★ $33.69 |
| Revenue Growth | ★ 14.17 | N/A |
| 52 Week Low | $70.12 | $510.06 |
| 52 Week High | $109.32 | $934.62 |
| Indicator | FTNT | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 30.95 |
| Support Level | $82.33 | $698.92 |
| Resistance Level | $86.96 | $856.67 |
| Average True Range (ATR) | 2.41 | 17.78 |
| MACD | 0.42 | -4.61 |
| Stochastic Oscillator | 95.40 | 15.24 |
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.